UCB and Microsoft seek personalized drugs in Neurology
Biopharmaceuticals UCB has announced the signing of an agreement with Microsoft to promote the development of new individualized drugs. Microsoft will provide technology from artificial intelligence (AI) and data specialists from both companies will work with UCB scientists to find fundamental correlations and patterns that enable the development of new individualized medications. The collaboration will … Read more